Viewing Study NCT02022956


Ignite Creation Date: 2025-12-24 @ 11:28 PM
Ignite Modification Date: 2026-01-01 @ 8:23 AM
Study NCT ID: NCT02022956
Status: COMPLETED
Last Update Posted: 2019-09-17
First Post: 2013-12-23
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age
Sponsor: Eisai Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module